









Markets
/
Stocks
/
nasdaq-sbfm
/

Sunshine Biopharma Inc

SBFM

1.470USD

-0.010-0.67%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

6.70MMarket Cap

LossP/E TTM



Sunshine Biopharma Inc

1.470

-0.010-0.67%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

94 / 175

Overall Ranking

284 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

7.000

Target Price

+376.19%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has over 32 additional generic prescription drugs. In addition, the Company is conducting a proprietary drug development program which consists of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio of pharmaceutical products consisting of approximately 61 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 702.52% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 34.87M.

Overvalued

The company’s latest PE is 0.04, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 174.71K shares, decreasing 55.48% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 54.09K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.43, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 9.41M, representing a year-over-year increase of 1.15%, while its net profit experienced a year-over-year increase of 258.25%.

Score

Industry at a Glance

Previous score

8.43

Change



Financials

8.87

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.51

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.39

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.37

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 5.27, which is higher than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 0.04, which is -145.91% below the recent high of -0.02 and 846.88% above the recent low of -0.31.

Score

Industry at a Glance

Previous score

5.27

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 94/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Sunshine Biopharma Inc is 7.00, with a high of 7.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

7.000

Target Price

+376.19%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Sunshine Biopharma Inc

SBFM

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 1.02, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 1.55 and the support level at 1.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.02

Change

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.012

Neutral

RSI(14)

52.218

Neutral

STOCH(KDJ)(9,3,3)

64.969

Neutral

ATR(14)

0.058

High Vlolatility

CCI(14)

62.366

Neutral

Williams %R

31.429

Buy

TRIX(12,20)

0.043

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.476

Sell

MA10

1.463

Buy

MA20

1.447

Buy

MA50

1.471

Sell

MA100

1.464

Buy

MA200

1.937

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 3.84%, representing a quarter-over-quarter decrease of 22.78%. The largest institutional shareholder is James Simons, holding a total of 54.09K shares, representing 1.19% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

L1 Capital Global Opportunities Master Fund Ltd.

142.24K

+5281.91%

SBI Securities Co., Ltd.

5.22K

+636.67%

Morgan Stanley Smith Barney LLC

3.83K

Chamoun (Malek)

1.85K

UBS Financial Services, Inc.

19.89K

+2190.90%

Osaic Holdings, Inc.

2.00

Slilaty (Steve N)

61.00

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.13, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.33. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.